NutriBand Inc. (NTRB) Stock Profile — Insider Trades & Financials

Revenue$346.1K

Net Income-$3.9M

EPS$-2.54

Gross Margin19.8%

Market Cap$47.7M

Price Performance

Historical data including institutional events

Loading price data...

Company Profile

Gareth Sheridan

CEO & Executive Director

Nutriband Inc. develops a portfolio of transdermal pharmaceutical products in the United States. The companyâs lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. It also develops AVERSA buprenorphine and AVERSA methylphenidate, and other transdermal pharmaceutical products. The company has commercial development and clinical supply agreement with Kindeva Drug Delivery. The company was incorporated in 2016 and is headquartered in Orlando, Florida.

Founded: 2016
Employees: 13
Headquarters: Orlando, Florida, United States

⚡

Core Efficiency

ROE?

-51.30%

ROA?

-45.99%

D/E Ratio?

0.12

Op. Margin?

-1121.30%

📊

Profitability Ratios

Net Margin?

-1118.99%

Loading company sections...

NutriBand Inc.

Price Performance

Company Profile

Core Efficiency

Profitability Ratios

Core Efficiency

Profitability Ratios

Earnings Calendar

Data Freshness